Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when his Department next plans to publish data derived from the HIV and AIDS reporting system (HARS); what data from HARS will be made available publicly and at what frequency; and if he will make a statement.
Answered by Jane Ellison
The human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) Reporting System (HARS) is a new, integrated reporting system for information on adults living with diagnosed HIV infection in England. It will be designated as an Official Statistic. A full data set from HARS is not yet available. HARS data relating to 2015 will be available in the summer of 2016 and published on an annual basis thereafter to inform and evaluate the public health response to HIV. The publication of the HARS data HARS data to inform commissioning will be made available to commissioners on a quarterly basis.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much the NHS spent on (a) all drugs, (b) cancer drugs and (c) drugs funded through the Cancer Drug Fund in each of the last five years for which figures are available.
Answered by George Freeman
Figures provided for Primary Care for total drug spend are the total of net ingredient cost (NIC) and for Secondary Care the cost of the medicines at NHS list price.
Cost of drugs in primary and secondary care, England: 2009-10 to 2013-14 | |||||
Total drugs |
| Cost (£ million) | |||
| Primary Care1 | Secondary Care2 | Total | ||
2009-10 | 8,621.4 | 3,890.8 | 12,512.2 | ||
2010-11 | 8,881.1 | 4,173.9 | 13,055.0 | ||
2011-12 | 8,778.0 | 4,497.6 | 13,275.5 | ||
2012-13 | 8,439.0 | 5,020.8 | 13,459.8 | ||
2013-14 | 8,703.2 | 5,780.6 | 14,483.8 | ||
Sources: Prescription Cost Analysis (PCA), IMS HEALTH: Hospital Pharmacy Audit | |||||
Cost of cancer drugs3 in primary and secondary care, England: 2009-10 to 2013-14 | |||||
Total drugs |
| Cost (£ million) | |||
| Primary Care1,4 | Secondary Care2 | Total | ||
2009-10 | 230.2 | 748.1 | 978.3 | ||
2010-11 | 228.2 | 846.1 | 1,074.3 | ||
2011-12 | 190.0 | 964.1 | 1,154.1 | ||
2012-13 | 142.0 | 1,119.6 | 1,261.6 | ||
2013-14 | 143.0 | 1,350.2 | 1,493.2 | ||
Sources: PCA, IMS HEALTH: Hospital Pharmacy Audit | |||||
Spend through the Cancer Drugs Fund between October 2010 and March 2014 |
| ||||
Year | Spend (£000’s) |
| |||
2010-11 (Q3 and Q4) | 38,254 |
| |||
2011-12 | 108,327 |
| |||
2012-13 | 175,334 |
| |||
2013-14 | 230,539 |
| |||
Source: Prior to April 2013, information supplied to the Department by strategic health authorities. From April 2013, information supplied by NHS England.
Notes:
1 Primary Care NIC is the basic cost of the drug, which does not take account of discounts, dispensing costs, fees or prescription charges income.
2 Secondary care cost is the cost of the medicines at NHS list price which may not reflect the price the hospital paid.
3 Cancer drugs are defined by British National Formulary Sections 8.1 Cytotoxic drugs,
8.2.3 Anti-lymphocyte monoclonal antibodies (but also used in other indications), 8.2.4 Other immunomodulating drugs (Interferon-Alfa, Aldesleukin, Bacillus Calmette-Guerin (B.C.G.), Lenalidomide, Pomalidomide, Thalidomide and Mifamurtide only), and 8.3 Sex hormones and hormone antagonists in malignant disease.
4 The main reason for the reduction in cancer drugs in Primary Care is the introduction of lower cost generic formulations.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what medicines the National Institute for Health and Care Excellence (NICE) (a) has evaluated and (b) intends to evaluate using the highly specialised technologies process; and what medicines his Department is planning to refer to NICE for assessment through that process.
Answered by George Freeman
The National Institute for Health and Care Excellence (NICE) has been asked to evaluate the following treatments under its highly specialised technologies (HST) programme:
Assessment title | Anticipated publication date |
Atypical haemolytic uraemic syndrome - eculizumab | January 2015 |
Gaucher disease (type 1) - eliglustat | August 2015 |
Mucopolysaccharidosis (type IVA) - elosulfase alfa | October 2015 |
Paediatric-onset hypophosphatasia - asfotase alfa | October 2015 |
NICE has not yet issued any final guidance through this programme.
A number of other medicines are being considered for referral to NICE’s HST programme through the established topic selection arrangements. Information on these is currently commercially confidential and cannot be released at this stage.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what prescriptions were dispensed in the community for the (a) prevention and (b) treatment of cardiovascular disease in (i) England and (ii) each local commissioning organisation in each of the last 10 years.
Answered by George Freeman
Dispensed prescription data does not distinguish between medicines dispensed for prevention and treatment. Available data for the total number of prescription items written in England for cardiovascular medicines, as defined by British National Formulary Section Chapter 2, Cardivascular system, and dispensed in the United Kingdom, is attached.
The England level data has been extracted from the Prescription Cost Analysis (PCA) database, administered by the Health and Social Care Information Centre (HSCIC), and is provided for the 10 year period 2004-05 to 2013-14. As PCA data are not available for local commissioning organisations, these data have been extracted from the HSCIC’s iView online database, which is based on ePACT data. Information has been provided by primary care trust for the period 2008-09 to 2012-13. For 2013-14, data are provided at clinical commissioning group level, reflecting the National Health Service organisational changes in April 2013. Information prior to 2008-09 is not available.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what proportion of patients have been recorded through the Quality and Outcomes Framework as having total cholesterol at 5mmol/l or less in (a) England and (b) each local commissioning organisation in each of the last five years.
Answered by Jane Ellison
Information on the number of patients on the four Quality and Outcomes Framework registers containing a measure of cholesterol is set out in the attached tables for England and for each clinical commissioning group/primary care trust in England.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what prescriptions have been dispensed in the community for the (a) prevention and (b) treatment of high cholesterol in (i) England and (ii) each local commissioning organisation in each of the last 10 years.
Answered by George Freeman
Dispensed prescription data does not distinguish between medicines dispensed for prevention and treatment. Available data for the total number of prescription items written in England for cardiovascular medicines, as defined by British National Formulary Section 2.12 Lipid-regulating drugs, and dispensed in the United Kingdom, is attached.
The England level data has been extracted from the Prescription Cost Analysis (PCA) database, administered by the Health and Social Care Information Centre (HSCIC), and is provided for the 10 year period 2004-05 to 2013-14. As PCA data are not available for local commissioning organisations, these data have been extracted from the HSCIC’s iView online database, which is based on ePACT data. Information has been provided by primary care trust for the period 2008-09 to 2012-13. For 2013-14, data are provided at clinical commissioning group level, reflecting the National Health Service organisational changes in April 2013. Information prior to 2008-09 is not available.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what hospital prescriptions have been used in the (a) prevention and (b) treatment of high cholesterol in (i) England and (ii) each local commissioning organisation in each of the last 10 years.
Answered by George Freeman
The available data, hospital dispensing information (HPAI) provided by IMS Health, does not distinguish between medicines used for prevention and treatment. Neither does it provide a breakdown at sub-national level for local commissioning organisations. The available data records usage in terms on volume dispensed.
The following table provides information on high cholesterol medicines, as defined by British National Formulary (BNF) Section 2.12 Lipid-regulating drugs, for hospitals in England, covering the 10 year period 2004-05 to 2013-14.
Volume of cholesterol medicines dispensed in hospitals in England, as defined by BNF Section 2.12 | |
Year | Volume of packs (000’s) |
2004-05 | 1,077.3 |
2005-06 | 1,170.9 |
2006-07 | 1,198.8 |
2007-08 | 1,214.0 |
2008-09 | 1,299.8 |
2009-10 | 1,326.6 |
2010-11 | 1,266.2 |
2011-12 | 1,196.1 |
2012-13 | 1,199.1 |
2013-14 | 1,202.7 |
Source: HPAI
Note that the volume of packs figures for hospitals are not comparable with the number of prescription items dispensed in the community.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department for Transport:
To ask the Secretary of State for Transport, how much investment has there been in the Chelmsford to London Liverpool Street rail line by (a) project and (b) type of investment in each of the last 10 financial years.
Answered by Claire Perry
The Department does not hold information about the Chelmsford to London Liverpool Street line in the format requested.
Details of infrastructure enhancements on the line are included in Network Rail’s enhancement plan for Control Period 4 (2009-2014) (available at http://www.networkrail.co.uk/WorkArea/DownloadAsset.aspx?id=30064785772)
For information about enhancements prior to 2009, information is available in the Network Route Plans for the Great Eastern Main Line on Network Rail’s website.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department for Transport:
To ask the Secretary of State for Transport, how many times and when rail services on the Chelmsford to London Liverpool Street line have been disrupted as a result of overrunning engineering works carried out by Network Rail in the last 12 months.
Answered by Claire Perry
The Department does not hold the information in the form requested. This would be a matter for Network Rail.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what information his Department holds on proposed investment in the Chelmsford to London Liverpool Street rail line in each of the next 10 years; and if he will make a statement.
Answered by Claire Perry
Investment plans for the line between Chelmsford and London Liverpool Street for Control Period 5 (for the period 2014-2019) are included in Network Rail’s Strategic Business Plan (available at the following web address: http://www.networkrail.co.uk/browse%20documents/strategicbusinessplan/cp5/supporting%20documents/our%20activity%20and%20expenditure%20plans/overarching%20cp5%20enhancements%20plan.pdf?cd=2).
For the five-year period beyond 2019, Network Rail published a draft Anglia Route Study on 5 November 2014:
http://www.networkrail.co.uk/long-term-planning-process/anglia-route-study/